A Phase I, Single-center, Non-randomized, Open-label, Mass Balance Study of Orally Administered [14C]-DZD8586 in Healthy Adult Male Participants
Latest Information Update: 10 Mar 2026
At a glance
- Drugs Birelentinib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Idiopathic thrombocytopenic purpura; Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors Dizal Pharmaceutical
Most Recent Events
- 10 Mar 2026 New trial record